



# SLIMEXIR®

The Silhouette-Refiner

SLIMEXIR® declares war on unloved problem areas. The ingenious combination of X-Melt®, a mix of Methylxanthines, extract of Artichoke (*Cynara scolymus*) and the polysaccharide Levan mutually support each other and efficiently combat excess fat. By means of X-Melt®, the maturation of Adipocytes is suppressed so that less fat is stored in the fat cells. Each of the individual components of SLIMEXIR® activates Lipolysis and causes the existing fat to increasingly fragment into fat globules and decompose. X-Melt® and the Artichoke extract stimulate the cutaneous microcirculation and improve the removal of the decomposed fat. Levan also provides a tightening film on the skin. SLIMEXIR® visibly and measurably refines the silhouette and when used regularly leads to a significantly slimmer abdomen.

SWISS EXPERTISE 

**RAHN**  
Your partner for excellence

---

## SCIENTIFICALLY PROVEN EFFECTS

- Prevents formation of new Adipocytes (*in-vitro* study)
- Reduces lipid accumulation in Adipocytes (*in-vitro* study)
- Stimulates degradation of existing fat (*in-vitro* study)
- Triggers fragmentation of lipid droplets (postulated mechanism) (*in-vitro* study)
- Leads to a significant reduction of abdomen volume (*in-vivo* study)



---

## ACTIVE INGREDIENTS

### X-Melt®




X-Melt®, the ingenious mix of four different Methylxanthines, has a convincing optimal triple effect. It suppresses the formation of Adipocytes, reduces the storage of fat (Lipogenesis) and stimulates lipid decomposition (Lipolysis).

### Artichoke extract



Artichoke extract contains a particularly high level of Caffeoylquinic acids. The plant extract supports X-Melt® by stimulating the lipid decomposition and providing an anti-oedematous effect.

### Levan




Levan is a polysaccharide made up of Fructose molecules. It activates lipid decomposition and due to its high molecular weight forms a firming film on the skin.

---

## MODE OF ACTION

X-Melt® on the one hand reduces Lipogenesis by inhibiting the maturation of pre-Adipocytes into Adipocytes, while on the other hand stimulates Lipolysis as the existing fat is separated into fat globules and decomposed. The Artichoke extract stimulates the cutaneous microcirculation to improve the removal of the decomposed fat. The high molecular weight Levan molecules provides a firming film on the skin.




## SLIMEXIR® REDUCES ADIPOCYTE FORMATION AND FAT STORAGE (*in-vitro* study)

**Method:** Morphology using microscopy; lipid storage using Sudan II dye and subsequent photospectrometry.

**Implementation:** Pre-Adipocytes were incubated with X-Melt® during their differentiation phase. The morphology and measurement of the lipid storage were subsequently measured. 0.005% X-Melt® is equivalent to 0.25% SLIMEXIR®. Reference substance: Caffeine.

**Result:** X-Melt® successfully reduces the formation of Adipocytes. The pre-Adipocytes retained their typical pointed shape and their differentiation was visibly reduced with fewer lipids stored.




## SLIMEXIR® STIMULATES THE DECOMPOSITION OF FAT (*in-vitro* study)


**Method:** Fatty acid release using a photometer.

**Implementation:** Incubation of primary subcutaneous Adipocytes obtained from a slightly overweight 46-year-old woman with the ingredients of SLIMEXIR® for 3 hours. Subsequent measurement of the fatty acids released.

**Result:** The ingredients of SLIMEXIR® increased the release of fatty acids by three times even with a 0.001 – 0.005% dose. SLIMEXIR® thus markedly stimulates lipid decomposition.



## SLIMEXIR® REFINES THE ABDOMEN (*in-vivo* study)




**Method:** Relative abdomen volume by means of fringe projection.

**Implementation:** Twice daily application of a foam containing 4% SLIMEXIR® in the abdominal region. Treatment

period: 2 months using 23 slightly overweight test subjects (BMI 26); age: 23 – 50 years. Measurement of the abdominal volume on Day 0, 28 and 56.

**Result:** SLIMEXIR® leads to a significant reduction in the volume of the abdomen:

- By 0.7% after 28 days with a positive effect on 70% of the test subjects
- By 1.1% after 56 days with a positive effect on 73% of the test subjects
- Maximum reduction of 9% (4.5 cm<sup>3</sup>)



### Application and Processing Information

Body care products to refine the silhouette and recontour the body. Can be used in O/W and W/O emulsions, gels and lotions.

**Recommended Use Level:** 2–10%

**INCI: EU:** Aqua, Levan, Cynara Scolymus Bud Extract, Decyl Glucoside, Phenethyl Alcohol, Citric Acid, Glucose, Caffeine, Theobromine, Methyl Xanthine, Paraxanthine **USA:** Water, Levan, Cynara Scolymus (Artichoke) Bud Extract, Decyl Glucoside, Phenethyl Alcohol, Citric Acid, Glucose, Caffeine, Theobromine, Methyl Xanthine, Paraxanthine **Japan:** Onsen-Sui, Levan, Cynara Scolymus (Artichoke) Bud Extract, Decyl Glucoside, Phenethyl Alcohol, Citric Acid, Glucose, Caffeine, Theobromine, Methyl Xanthine, Paraxanthine



**RAHN AG**

Dörflistrasse 120  
CH-8050 Zürich  
Tel. +41 44 315 42 00  
Fax +41 44 315 42 45

RAHN GmbH  
Hahnstrasse 70  
DE-60528 Frankfurt am Main  
Tel. 0800 1 816 015  
Fax 0800 1 816 016

RAHN (UK) Ltd.  
75 Park Road  
GB-Peterborough PE1 2TN  
Tel. 0800 0 323 743  
Fax 0800 0 323 744

RAHN France  
91 rue de Faubourg Saint-Honoré  
FR-75008 Paris  
Tel. +41 44 315 42 00  
Fax +41 44 315 42 45

RAHN USA Corp.  
1005 North Commons Drive  
Aurora, Illinois 60504, USA  
Tel. +1 630 851 42 20  
Fax +1 630 851 48 63

cosmetics@rahn-group.com  
www.rahn-group.com



**DISCLAIMER**

Utilisation of this document or parts thereof as well as product names for commercial or industrial applications is subject to explicit written approval by RAHN AG. This information is based on our own experience to date and we believe it to be reliable. It is intended only as a guide to use at your discretion and risk. We cannot guarantee favourable results and assume no liability in connection with its use, or the use of the methods or products described. None of this information is to be taken as a license to operate under, or a recommendation to infringe patents.

Version: 02/2014